✦ LIBER ✦

Reversible bilateral optic neuritis after Infliximab discontinuation in a patient with Crohn's disease

✍ Scribed by Taxiarchis Felekis; Konstantinos Katsanos; Dimitrios Christodoulou; Ioannis Asproudis; Epameinondas V. Tsianos

Book ID: 119223135
Publisher: Oxford University Press
Year: 2009
Tongue: English
Weight: 128 KB
Volume: 3
Category: Article
ISSN: 1873-9946
DOI: 10.1016/j.crohns.2009.04.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Retrobulbar optic neuritis associated wi

Retrobulbar optic neuritis associated with infliximab in a patient with Crohn's disease

✍ Asma Ouakaa-Kchaou; Dalila Gargouri; Sonia Trojet; Rania Hefaiedh; Hela Elloumi; 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 296 KB

Infliximab treatment in a patient with C

Infliximab treatment in a patient with Crohn’s disease on haemodialysis

✍ K. Kume; M. Yamasaki; I. Yoshikawa; M. Harada 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 35 KB

Symptomatic hypokalemia associated with

Symptomatic hypokalemia associated with infliximab in a patient with Crohn's disease

✍ George Karamanolis; Charalambos Tzathas; Konstantinos Triantafyllou; Zaharias Ts 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

Lymphomatoid papulosis in a patient with

Lymphomatoid papulosis in a patient with Crohn's disease treated with infliximab

✍ William Outlaw; Alan Fleischer; Richard Bloomfeld 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

Transient menorrhagia without adalimumab

Transient menorrhagia without adalimumab discontinuation in a patient with Crohn's disease

✍ Konstantinos H. Katsanos; Vasileios E. Tsianos; Epameinondas V. Tsianos 📂 Article 📅 2010 🏛 Oxford University Press 🌐 English ⚖ 133 KB

Salmonella septic arthritis in a patient

Salmonella septic arthritis in a patient with Crohn's disease on infliximab

✍ Jean Y. Rim; Allan R. Tenorio 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

The use of tumor necrosis factor a (TNFa) inhibitors such as infliximab, etanercept, and adalimumab for various autoimmune diseases, including Crohn's disease (CD) and ulcerative colitis (UC), has increased in the past few years. While associated with symptomatic relief in many patients, the use of